Catalog No.
DHC09613
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1
Clonality
Monoclonal
Target
p185erbB2, HER2, NGL, Tyrosine kinase-type cell surface receptor HER2, NEU, MLN 19, Proto-oncogene Neu, MLN19, ERBB2, Proto-oncogene c-ErbB-2, CD340, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P04626 & P07766
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific
Clone ID
M802
Note
For research use only. Not suitable for clinical or therapeutic use.
Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience., PMID:40380283
Aptamer-enhanced ultrasensitive electrochemical detection of HER-2 in breast cancer diagnosis using ZnO tetrapod-K4PTC nanohybrids., PMID:40382399
Dual-Signal Probing of Molecular Subtypes of Breast Cancer: Synergistic Chirality and Charge-Transfer Effect Enable Enhanced Accuracy., PMID:40388600
Prediction models of breast cancer molecular subtypes based on multimodal ultrasound and clinical features., PMID:40389869
Erbin interacts with NHERF1 and Ezrin to stabilize a membrane ErbB2 signaling complex in HER2-positive breast cancer., PMID:40390040
Clinical application of trastuzumab and docetaxel in the chemotherapy of human epidermal growth factor receptor 2 positive breast cancer patients., PMID:40391840
Patterns of presentation, treatment, and survival among older adults with metastatic breast cancer: Results from a large prospective registry., PMID:40393173
Intra-tumoral spatial heterogeneity in breast cancer quantified using high-dimensional protein multiplexing and single cell phenotyping., PMID:40399910
Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy., PMID:40404737
Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment study., PMID:40405072
miRNA panel from HER2+ and CD24+ plasma extracellular vesicle subpopulations as biomarkers of early-stage breast cancer., PMID:40405296
Prevalence and clinicopathological features of human epidermal growth factor receptor-2-low breast cancers: A single-center experience., PMID:40411392
Breast cancer early detection and molecular subtype prediction by combination of Raman spectroscopy with deep learning., PMID:40412234
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells., PMID:40418656
Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget's disease., PMID:40421956
Subtype-specific dysregulation of biogenic amine-related genes and miRNAs in breast cancer: identification of DRD2, HRH2, and HRH4 as potential therapeutic targets in TNBC and HER2+ subtypes., PMID:40425926
Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China., PMID:40426093
Hedgehog inhibitors exert anti-proliferation effects and synergistically interact with trastuzumab in HER2-positive gastric cancer models., PMID:40426308
LIFR-Mediated ERBB2 Signaling Is Essential for Successful Embryo Implantation in Mice., PMID:40427591
Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine., PMID:40428777
CD44 Marks Dormant Tumor Cells After HER2 Inhibition in Breast Cancer Cells., PMID:40430044
Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma., PMID:40433373
Pyrotinib promotes the antitumor effect of T-DM1 by increasing drug endocytosis in HER2-positive breast cancer., PMID:40437017
Real-world data on trastuzumab emtansine (TDM1) efficacy and safety: Results of a single-centre retrospective study of HER2-positive metastatic breast cancer patients., PMID:40437155
Metastatic breast cancer through the Oncotype DX Breast Recurrence Score®: insights from a small cohort study., PMID:40437301
Updated efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in elderly women with HR+/HER-2 metastatic or advanced breast cancer: patient-level network meta-analysis., PMID:40440494
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial., PMID:40441802
Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency., PMID:40445758
Chemically Engineered Affinity Protein Drugs for Covalent Targeted Cancer Therapy., PMID:40445865
Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations., PMID:40448190
T-cell activation enhances anti-HER2-mediated antibody-dependent cellular cytotoxicity in gastric cancer., PMID:40455140
Assessing the Relationship among Tumor Size, Lymph Node Status, and ER/PR/HER2 Expression in Patients with Breast Cancer., PMID:40460385
Mechanisms of resistance to antibody-drug conjugates in cancers., PMID:40460510
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer., PMID:40464376
Effect of HER2-low expression on the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer., PMID:40467708
Radiation therapy in clinically node positive HER2 positive breast cancer after primary systemic therapy and breast conserving surgery: pooled analysis of TRYPHAENA and NeoSphere trials., PMID:40468250
Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report., PMID:40468744
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis., PMID:40468999
Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors., PMID:40469307
Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China., PMID:40472040
A homogeneous mass-encoded strategy for mass spectrometric biosensing of multiplex proteins., PMID:40480694
Axillary staging with 18F-FDG PET/CT in early breast cancer: impact of tumor subtypes., PMID:40482189
Improved Sampling Method to Enhance the Positive Rate of HER2 Detection in Gastric Cancer., PMID:40485523
Predictive power of tertiary lymphoid structure for prognosis and neoadjuvant chemotherapy response in HER2-positive breast cancer., PMID:40489875
ERBB2-Low Expression by Race and Ethnicity Among Patients With Triple-Negative Breast Cancer., PMID:40498483
Impact of age and comorbidities on real-world outcomes in advanced breast cancer patients treated with palbociclib in first line: a nation-wide Danish retrospective study., PMID:40500959
RNF213-Dependent EGFR and HER2 Activation Regulates Specific Downstream Signaling Pathways in Human Cancer Cells., PMID:40503863
Hereditary breast cancer beyond BRCA: clinicopathological characteristics and long-term outcomes., PMID:40504267
Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type., PMID:40512776
For research use only. Not for human or drug use.
